We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00243347
Recruitment Status : Completed
First Posted : October 24, 2005
Results First Posted : October 17, 2013
Last Update Posted : October 17, 2013
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Carcinoma
Non-Small-Cell Lung Carcinoma
Head and Neck Neoplasms
Intervention: Drug: AZD2171

  Participant Flow

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Cediranib 30 mg Cediranib 30mg/Day

Baseline Measures
   Cediranib 30 mg 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 58.1  (12.32) 
[Units: Participants]
Female   4 
Male   15 

  Outcome Measures

1.  Primary:   Change From Baseline in Standardised Uptake Value (SUVmax) as Measured by 2-[F-18]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET)   [ Time Frame: Randomisation until Day 22 ]

2.  Secondary:   Change From Baseline in Mean Arterial Blood Pressure (MAP)   [ Time Frame: Randomisation until Day 22 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information